<story><title>FDA approves new ADHD drug for children</title><url>https://www.axios.com/fda-approves-new-adhd-drug-for-children-d7bb24d4-7bf2-4a5e-a505-833ed57dee7a.html</url></story><parent_chain></parent_chain><comment><author>nerdbaggy</author><text>Seems that lots of people only think ADHD people have a hard time paying attention. If it was that simple I would be so happy. Here are just a few of the things I struggle with.&lt;p&gt;- Will power. People with ADHD struggle sooooo much with will power. It’s a constant struggle with everything in life and really wears you down.&lt;p&gt;- Constantly putting on a fake front pretending you don’t have ADHD.&lt;p&gt;- Rejection sensitivity&lt;p&gt;- Feeling inadequate, and unset at yourself for not being able to perform like peers&lt;p&gt;- Emotions swinging from happy to angry in a flash&lt;p&gt;- not being able to maintain friendships&lt;p&gt;- People thinking it’s not a real condition. Unless you have it you can’t even come close to understanding how much of a challenge every day is.&lt;p&gt;- Medication only helps with the attention issue for maybe 8 hours. It doesn’t help with the other 95% of the issues&lt;p&gt;This is by far the best what is it like &lt;a href=&quot;https:&amp;#x2F;&amp;#x2F;gekk.info&amp;#x2F;articles&amp;#x2F;adhd.html&quot; rel=&quot;nofollow&quot;&gt;https:&amp;#x2F;&amp;#x2F;gekk.info&amp;#x2F;articles&amp;#x2F;adhd.html&lt;/a&gt; and here is the corresponding HN &lt;a href=&quot;https:&amp;#x2F;&amp;#x2F;news.ycombinator.com&amp;#x2F;item?id=22129777&quot; rel=&quot;nofollow&quot;&gt;https:&amp;#x2F;&amp;#x2F;news.ycombinator.com&amp;#x2F;item?id=22129777&lt;/a&gt;</text></comment>
<story><title>FDA approves new ADHD drug for children</title><url>https://www.axios.com/fda-approves-new-adhd-drug-for-children-d7bb24d4-7bf2-4a5e-a505-833ed57dee7a.html</url></story><parent_chain></parent_chain><comment><author>PragmaticPulp</author><text>For anyone curious about the proposed mechanism of action, care of the Wikipedia page &lt;a href=&quot;https:&amp;#x2F;&amp;#x2F;en.wikipedia.org&amp;#x2F;wiki&amp;#x2F;Viloxazine&quot; rel=&quot;nofollow&quot;&gt;https:&amp;#x2F;&amp;#x2F;en.wikipedia.org&amp;#x2F;wiki&amp;#x2F;Viloxazine&lt;/a&gt;&lt;p&gt;&amp;gt; Viloxazine, like imipramine, inhibited norepinephrine reuptake in the hearts of rats and mice; unlike imipramine, it did not block reuptake of norepinephrine in either the medullae or the hypothalami of rats. As for serotonin, while its reuptake inhibition was comparable to that of desipramine (i.e., very weak), viloxazine did potentiate serotonin-mediated brain functions in a manner similar to amitriptyline and imipramine, which are relatively potent inhibitors of serotonin reuptake.[11] Unlike any of the other drugs tested, it did not exhibit any anticholinergic effects.[11]&lt;p&gt;&amp;gt; More recent research has found that the mechanism of action of viloxazine may be more complex than previously assumed.[12] It appears to act as a potent antagonist of 5-HT2B receptors and as a potent agonist of 5-HT2C receptors.[12] These actions may be involved in its effectiveness for ADHD.[12]&lt;p&gt;&amp;gt; It has also been found to up-regulate GABAB receptors in the frontal cortex of rats.[13]&lt;p&gt;As always, a drug&amp;#x27;s effects cannot be interpreted simply by looking at binding affinities. It&amp;#x27;s important to focus on the actually human clinical trials. The binding affinities are interesting in the context of neuroscience and drug research, but less so for treatment decisions.</text></comment>